HIV/AIDS Vaccine Development

Efficacy of recombinant glycoprotein 120 vaccine reported

Published in AIDS Weekly, October 24th, 2005

Researchers report results of a clinical trial assessing the efficacy of a recombinant glycoprotein 120 vaccine in a recent issue of the Journal of Infectious Diseases.

"The first trial of the efficacy of a human immunodeficiency virus (HIV)-1 vaccine was conducted in North America and the Netherlands between 1998 and 2003. This multicenter, randomized, placebo-controlled trial of a recombinant glycoprotein 120 vaccine included 5,403 initially HIV-negative volunteers who were monitored for 3 years," investigators in the United States and Canada report.

"The 368 subjects who acquired HIV-1 infection were monitored for 2 years by use of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2005-10-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry